GlassScriptPhysician profile
Darius R Mcgee
NPI 1619004744
$2,785.54
in general payments reported to CMS, 2019-2025
21 companies · $807 in 2025
The $807 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $574 · 2022: $347 · 2023: $572 · 2024: $485 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $674.54 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.42 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $125.61 | 2021-2022 | |
| Novo Nordisk INC | $93.55 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $91.52 | 2021-2023 | Arexvy |
| Daiichi Sankyo INC. | $82.71 | 2021 | |
| Lilly USA, LLC | $75.27 | 2021-2023 | Mounjaro |
| Mylan Specialty L.P. | $53.49 | 2022 | |
| Amgen INC. | $48.75 | 2022-2023 | Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.39 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $27.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.34 | 2025 | |
| Ibsa Pharma INC. | $17.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.07 | 2025 | |
| Sanofi Pasteur INC. | $16.64 | 2022 | |
| Abbott Laboratories | $16.12 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $15.02 | 2024 | |
| Corium, LLC | $14.42 | 2022 | |
| Astellas Pharma US INC | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darius Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.